MEDIVATION, INC.

Medivation is based out of San Francisco. Medivation, Inc. (Medivation), together with its operating subsidiaries, is a biopharmaceutical company engaged in the acquisition, research and development of promising medical technologies. The Company's portfolio consists of small molecule drugs in development to treat three medical needs: Dimebon for the treatment of Alzheimer's disease, Dimebon for the treatment of Huntington's disease, and MDV3100 for the treatment of hormone-refractory prostate cancer. The Company has two operating subsidiaries: Medivation Neurology, Inc. (MNI) that holds the Company's Dimebon technology, and Medivation Prostate Therapeutics, Inc. (MPT) that holds the Company's MDV300 series technology.Whalewisdom has at least 1 13G filings, and 247 Form 4 filings The firm has no submitted 13F filings and does not appear to be an investment advisor.